Creative Capital Management Investments’s AstraZeneca AZN Stock Holding History

Creative Capital Management Investments’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.98K	Buy	21 +14	+200%	+$2.63K	﹤0.01%	491
2026 Q1	$1.38K	Sell	7 -1	-13%	-$193	﹤0.01%	280
2025 Q4	$1.38K	Buy	+8	New	+$1.4K	﹤0.01%	279

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Creative Capital Management Investments's AZN Position: Q2 2026 in Review

Creative Capital Management Investments increased its AstraZeneca (AZN) stake by 200% in Q2 2026, buying an estimated $2.63K and bringing the position to 21 shares worth $3.98K. The position accounts for ﹤0.01% of the portfolio, ranked #491.

Creative Capital Management Investments first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Creative Capital Management Investments held 21 shares of AstraZeneca worth $3.98K as of Q2 2026.
Creative Capital Management Investments bought 14 AstraZeneca shares in Q2 2026, an estimated $2.63K.
AstraZeneca made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #491 holding.
Creative Capital Management Investments first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.